Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review.
Adolescent
Adult
Aged
Aged, 80 and over
Allied Health Personnel
/ statistics & numerical data
Behavioral Risk Factor Surveillance System
Cross-Sectional Studies
/ statistics & numerical data
Europe
/ epidemiology
Evaluation Studies as Topic
Humans
Knowledge
Middle Aged
Outcome Assessment, Health Care
/ statistics & numerical data
Pharmacoepidemiology
/ methods
Pharmacovigilance
Prospective Studies
Retrospective Studies
Risk Management
/ methods
Safety
Self Report
/ statistics & numerical data
Young Adult
Journal
Pharmaceutical medicine
ISSN: 1179-1993
Titre abrégé: Pharmaceut Med
Pays: New Zealand
ID NLM: 101471195
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
accepted:
01
10
2020
pubmed:
4
11
2020
medline:
24
8
2021
entrez:
3
11
2020
Statut:
ppublish
Résumé
European Pharmacovigilance regulatory guidance recommends the evaluation of additional risk minimisation measures (aRMMs) with process indicators and outcomes. Evaluation of both measures within the same evaluation helps to establish the relationship between the implementation of aRMMs (across process indicators) and the impact on drug safety-related outcomes. The term risk minimisation evaluation (RMEv) was used to describe a study or group of studies that assesses the effectiveness of aRMMs for one specific product. The objective of this systematic review was to describe the characteristics and results of RMEv that include both process indicators and outcomes as well as those of studies that conform the RMEv in Europe. We conducted a systematic search in the European Union Register of Post-Authorization Studies, PubMed and grey literature (Google and abstracts of the International Conference on Pharmacoepidemiology and Therapeutic Risk Management) to identify studies that assessed the effectiveness of aRMMs including at least one European country, from 1 January, 2011 to 12 October, 2019. Identified studies linked to one product were considered part of the product RMEv. Only RMEv that included both process indicators and outcomes (behavioural and/or health/safety outcomes) were eligible. Data were abstracted from reports, manuscripts and abstracts. Eighteen of 102 (18%) RMEv had both process indicators and outcomes, and were included in this review. Of the 18 RMEv, ten consisted of one study only, five of two studies, and three of three or more studies. A total of 30 studies were included within the 18 RMEv. The designs of the studies were: 19 (63%) cross-sectional surveys (47% targeted patients and 89% healthcare professionals), 17 (57%) retrospective studies (47% using pre/post approach) and 3 (10%) prospective studies. Nineteen studies included process indicators that were receipt (n = 14), use (n = 12), knowledge (n = 17) and self-reported behaviour (n = 15). Regarding outcomes, 67% of the 18 RMEv evaluated behavioural outcomes and 50% health/safety outcomes. Three of the 18 RMEv evaluated both behavioural and health/safety outcomes. For five RMEv, correlations between process indicators and outcomes were performed, two at the patient level. Results were available for 14 of the 18 RMEv. In healthcare professional surveys, the median percentage was 57% for receipt, 92% for reading, 80% for use, 77% for knowledge and 74% for behaviour. In patient surveys, the median percentage was 56% for receipt, 87% for reading, 65% for use, 47% for knowledge and 69% for behaviour. Knowledge was better in healthcare professionals than patients (p < 0.05). Of the three RMEv with a correlation analysis, only one found a positive trend for a lower occurrence of outcomes as process indicators improved, though this was not statistically significant. A minority of RMEv assessed both process indicators and outcomes. More RMEv require approaches that correlate process indicators and outcomes at the patient level to evaluate more comprehensively the implementation of aRMMs.
Sections du résumé
BACKGROUND
European Pharmacovigilance regulatory guidance recommends the evaluation of additional risk minimisation measures (aRMMs) with process indicators and outcomes. Evaluation of both measures within the same evaluation helps to establish the relationship between the implementation of aRMMs (across process indicators) and the impact on drug safety-related outcomes. The term risk minimisation evaluation (RMEv) was used to describe a study or group of studies that assesses the effectiveness of aRMMs for one specific product.
OBJECTIVES
The objective of this systematic review was to describe the characteristics and results of RMEv that include both process indicators and outcomes as well as those of studies that conform the RMEv in Europe.
METHODS
We conducted a systematic search in the European Union Register of Post-Authorization Studies, PubMed and grey literature (Google and abstracts of the International Conference on Pharmacoepidemiology and Therapeutic Risk Management) to identify studies that assessed the effectiveness of aRMMs including at least one European country, from 1 January, 2011 to 12 October, 2019. Identified studies linked to one product were considered part of the product RMEv. Only RMEv that included both process indicators and outcomes (behavioural and/or health/safety outcomes) were eligible. Data were abstracted from reports, manuscripts and abstracts.
RESULTS
Eighteen of 102 (18%) RMEv had both process indicators and outcomes, and were included in this review. Of the 18 RMEv, ten consisted of one study only, five of two studies, and three of three or more studies. A total of 30 studies were included within the 18 RMEv. The designs of the studies were: 19 (63%) cross-sectional surveys (47% targeted patients and 89% healthcare professionals), 17 (57%) retrospective studies (47% using pre/post approach) and 3 (10%) prospective studies. Nineteen studies included process indicators that were receipt (n = 14), use (n = 12), knowledge (n = 17) and self-reported behaviour (n = 15). Regarding outcomes, 67% of the 18 RMEv evaluated behavioural outcomes and 50% health/safety outcomes. Three of the 18 RMEv evaluated both behavioural and health/safety outcomes. For five RMEv, correlations between process indicators and outcomes were performed, two at the patient level. Results were available for 14 of the 18 RMEv. In healthcare professional surveys, the median percentage was 57% for receipt, 92% for reading, 80% for use, 77% for knowledge and 74% for behaviour. In patient surveys, the median percentage was 56% for receipt, 87% for reading, 65% for use, 47% for knowledge and 69% for behaviour. Knowledge was better in healthcare professionals than patients (p < 0.05). Of the three RMEv with a correlation analysis, only one found a positive trend for a lower occurrence of outcomes as process indicators improved, though this was not statistically significant.
CONCLUSIONS
A minority of RMEv assessed both process indicators and outcomes. More RMEv require approaches that correlate process indicators and outcomes at the patient level to evaluate more comprehensively the implementation of aRMMs.
Identifiants
pubmed: 33141411
doi: 10.1007/s40290-020-00361-w
pii: 10.1007/s40290-020-00361-w
doi:
Types de publication
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
387-400Références
Rubino A, Artime E. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006–2015. Expert Opin Drug Saf. 2017;16:877–84.
doi: 10.1080/14740338.2017.1335303
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VIII: post-authorisation safety studies (Rev 2). 2016. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-2_en.pdf
European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module XVI: risk minimisation measures: selection of tools and effectiveness indicators (Rev 2). 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf
Rubino A, Artime E. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015. Expert Opin Drug Saf. 2017; p. 1–8.
Artime E, Qizilbash N, Garrido-Estepa M, Vora P, Soriano-Gabarró M, Asiimwe A, et al. Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opin Drug Saf. 2019;18:443–54.
doi: 10.1080/14740338.2019.1612875
Vora P, Artime E, Soriano-Gabarró M, Qizilbash N, Singh V, Asiimwe A. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies. Pharmacoepidemiol Drug Saf. 2018;27:695–706.
doi: 10.1002/pds.4434
Mazzaglia G, Straus SMJ, Arlett P, da Silva D, Janssen H, Raine J, et al. Study design and evaluation of risk minimization measures: a review of studies submitted to the European Medicines Agency for cardiovascular, endocrinology, and metabolic drugs. Drug Saf. 2018;41:191–202.
doi: 10.1007/s40264-017-0604-4
YERVOY
Evaluation of the effectiveness of Eliquis
Evaluation of the effectiveness of the abatacept (Orencia
Evaluation of the effectiveness of the belatacept (Nulojix
Post Authorisation Safety Study (PASS) to evaluate the risks of hepatotoxicity and nephrotoxicity from administration of methoxyflurane (Penthrox
Evaluation of the effectiveness of Penthrox
Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, et al. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019;33:311–9.
pubmed: 31933191
Objective assessment of metabolic monitoring in patients treated with Seroquel
Drug utilization study on the prescribing indications for CPA/EE in 5 European countries. https://www.encepp.eu/encepp/viewResource.htm?id=30829 . Accessed 16 Oct 2020.
Nyeland ME, Laursen MV, Callréus T. Evaluating the effectiveness of risk minimisation measures: the application of a conceptual framework to Danish real-world dabigatran data. Pharmacoepidemiol Drug Saf. 2017;26:607–14.
doi: 10.1002/pds.4203
Quinn D, Donegan K. Usage of valproate in women in the UK. Pharmacoepidemiol Drug Saf. 2016;25(Suppl.):3–680.
Mabthera drug utilisation study and patient alert card evaluation in non-oncology patients in Europe: an infusion centre based approach. https://www.encepp.eu/encepp/viewResource.htm?id=24913 . Accessed 16 Oct 2020.
A drug utilization study in patients treated with Exelon
A drug utilisation study of domperidone in Europe using databases. https://www.encepp.eu/encepp/viewResource.htm?id=22405 . Accessed 16 Oct 2020.
Drug utilisation study, in five European countries, using cross sectional analysis, to assess the extent of prescriptions of trimetazidine for its withdrawn ophthalmological and ENT indications among general practitioners, ophthalmologists and ENT special. https://www.encepp.eu/encepp/viewResource.htm?id=18050 . Accessed 16 Oct 2020.
Evaluation of the effectiveness of risk minimization measures: trimetazidine drug utilization study in European countries using databases: analysis for France, Hungary, Romania and Spain. https://www.encepp.eu/encepp/viewResource.htm?id=28831 . Accessed 16 Oct 2020.
Drug utilization study of cyproterone/ethinylestradiol (Diane
Agyemang E, Bailey L, Talbot J. Additional risk minimisation measures for medicinal products in the European Union: a review of the implementation and effectiveness of measures in the United Kingdom by one marketing authorisation holder. Pharmaceut Med. 2017;31:101–12.
pubmed: 28413313
pmcid: 5376384
A joint Drug Utilisation Study (DUS) of valproate and related substances, in Europe, using databases. https://www.encepp.eu/encepp/viewResource.htm?id=32834 . Accessed 16 Oct 2020.
Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions: systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84:419–33.
doi: 10.1111/bcp.13469
Farcas A, Huruba M, Mogosan C. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register. Br J Clin Pharmacol. 2019;85:476–91.
doi: 10.1111/bcp.13824
CIOMS Working Group IX. Practical approaches to risk minimisation for medicinal products: report of CIOMS Working Group IX. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS); 2014.
Charlton RA, Bettoli V, Bos HJ, Engeland A, Garne E, Gini R, et al. The limitations of some European healthcare databases for monitoring the effectiveness of pregnancy prevention programmes as risk minimisation measures. Eur J Clin Pharmacol. 2018;74:513–20.
doi: 10.1007/s00228-017-2398-9
Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions: systematic review and methodological considerations. Br J Clin Pharmacol. 2018;84:419–33.
doi: 10.1111/bcp.13469
Pacurariu A, Plueschke K, McGettigan P, Morales DR, Slattery J, Vogl D, et al. Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. BMJ Open. 2018;8:1–10.
doi: 10.1136/bmjopen-2018-023090
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (Revision 7). EMA/95098/2010. https://www.encepp.eu/standards_and_guidances . Accessed 16 Oct 2020.
Møllebæk M, Kaae S, De Bruin ML, Callréus T, Jossan S, Hallgreen CE. The effectiveness of direct to healthcare professional communication: a systematic review of communication factor studies. Res Soc Adm Pharm. 2019;15:475–82.
doi: 10.1016/j.sapharm.2018.06.015
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. ENCePP guide on methodological standards in pharmacoepidemiology. https://www.encepp.eu/standards_and_guidances/methodologicalGuide4_1_1.shtml . Accessed 19 Aug 2017.
Smith MY, Russell A, Bahri P, Mol PGM, Frise S, Freeman E, Morrato EH. The RIMES statement: a checklist to assess the quality of studies evaluating risk minimization programs for medicinal products. Drug Saf. 2018;41(4):389–401.
doi: 10.1007/s40264-017-0619-x
Russell AM, Morrato EH, Lovett RM, Smith MY. Quality of reporting on the evaluation of risk minimization programs: a systematic review. Drug Saf. 2020; p. 1–20.
The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Annex 2 to the guide on methodological standards in pharmacoepidemiology. https://www.encepp.eu/standards_and_guidances . Accessed 16 Oct 2020.
Brosch S, de Ferran AM, Newbould V, Farkas D, Lengsavath M, Tregunno P. Establishing a framework for the use of social media in pharmacovigilance in Europe. Drug Saf. 2019;42:921–30.
doi: 10.1007/s40264-019-00811-8